Royalty Pharma plc
RPRX
$31.79
$0.511.63%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 858.98M | 1.15B | 673.24M | 798.86M | 1.13B |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 19.56M | 19.10M | 18.76M | 19.52M | 20.50M |
| Total Other Non-Cash Items | -1.15B | -1.37B | -923.82M | -1.01B | -1.37B |
| Change in Net Operating Assets | 3.04B | 3.00B | 2.90B | 2.81B | 3.21B |
| Cash from Operations | 2.77B | 2.80B | 2.67B | 2.62B | 2.99B |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.68B | -3.17B | -2.43B | -1.60B | -2.07B |
| Cash from Investing | -2.68B | -3.17B | -2.43B | -1.60B | -2.07B |
| Total Debt Issued | 1.47B | 1.82B | 1.82B | 350.00M | 350.00M |
| Total Debt Repaid | -- | -350.00M | -1.35B | -1.35B | -1.35B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -229.65M | -207.24M | -250.32M | -304.76M | -304.76M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -376.47M | -372.15M | -367.84M | -363.50M | -358.33M |
| Other Financing Activities | -503.97M | -504.63M | -499.85M | -482.12M | -485.67M |
| Cash from Financing | 361.15M | 387.21M | -646.77M | -2.15B | -2.15B |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 452.02M | 13.60M | -408.43M | -1.13B | -1.23B |
